Moleculin Biotech, Inc.
Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Registre Officiel
Analyse Qualité IA
Détails du Score de Confiance
Liens Rapides
Points forts du site
🌟 Entreprises similaires de confiance
Aquestive Therapeutics, Inc.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. They develop orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has commercialized products marketed by its licensees and is the exclusive manufacturer of these licensed products.
Addex Therapeutics Ltd.
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Their pipeline includes compounds targeting post-stroke recovery, substance use disorder and chronic cough. The company utilizes its expertise in allosteric modulation for drug discovery.
SERVIER OUTRE-MER
Servier is an independent international pharmaceutical company focused on therapeutic progress for patients. They invest significantly in research and development, particularly in oncology, cardiometabolism, and neuroscience. Servier is known for its long-term vision and commitment to patients' needs.